Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
Relay Therapeutics (RLAY) Stock Price & Analysis
320 Followers
RLAY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.70 - $12.63
Previous Close$8.6
Volume693.11K
Average Volume (3M)1.36M
Market Cap
$1.14B
Enterprise Value$1.04B
Total Cash (Recent Filing)$152.87M
Total Debt (Recent Filing)$52.31M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 07, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding132,741,677
10 Day Avg. Volume1,686,933
30 Day Avg. Volume1,358,982
Standard Deviation0.19
R-Squared0.19
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.23
Price to Sales (P/S)36.06
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue29.47
Enterprise Value/Gross Profit40.75
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$21.29Price Target Upside147.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Relay Therapeutics News
PremiumCompany Announcements
Relay Therapeutics Advances Cancer Treatment and Expands Drug Pipeline
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination therapy reduced the risk of disease worsening or death by 57% compared to existing treatments.
Partnerships And CollaborationsClinical trial collaboration inked with Pfizer is viewed as an incremental positive for Relay Therapeutics.
Regulatory And Market ExpansionThe company plans to expand its PIK3CA program into vascular malformations, potentially increasing the addressable market from 5-15k PROS patients to around 170k in the US.
Bears Say
Financial ImpactThere will be no further milestones or other payments due from Roche after terminating the collaboration agreement with Relay Therapeutics.
Partnership TerminationRoche terminated its collaboration agreement with Relay Therapeutics for the SHP2 inhibitor migoprotafib/RLY-1971.
Resource AllocationRelay Therapeutics is minimizing resources on the asset lirafugratinib despite accruing background data.
---
Ownership Overview
33.94% Insiders
26.87% Mutual Funds
15.21% Other Institutional Investors
23.99% Public Companies and
Individual Investors
RLAY FAQ
What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $5.70 and its highest was $12.63 in the past 12 months.
What is Relay Therapeutics’s market cap?
Currently, no data Available
When is Relay Therapeutics’s upcoming earnings report date?
Relay Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Relay Therapeutics’s earnings last quarter?
Relay Therapeutics released its earnings results on May 02, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.727 by $0.107.
Is Relay Therapeutics overvalued?
According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued.
Does Relay Therapeutics pay dividends?
Relay Therapeutics does not currently pay dividends.
What is Relay Therapeutics’s EPS estimate?
Relay Therapeutics’s EPS estimate is -$0.73.
How many shares outstanding does Relay Therapeutics have?
Relay Therapeutics has 132,741,680 shares outstanding.
What happened to Relay Therapeutics’s price movement after its last earnings report?
Relay Therapeutics reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.727. Following the earnings report the stock price went down -0.565%.
Which hedge fund is a major shareholder of Relay Therapeutics?
Among the largest hedge funds holding Relay Therapeutics’s share is Baker Bros Advisors LP. It holds Relay Therapeutics’s shares valued at 10M.
---
Relay Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.29 (147.56% Upside)
$21.29 (147.56% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 422.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $184.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.3%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.19%
12-Months-Change
Fundamentals
Return on Equity
-40.40%
Trailing 12-Months
Asset Growth
-18.90%
Trailing 12-Months
Company Description
Relay Therapeutics
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
---
RLAY Stock 12 Month Forecast
Average Price Target
$21.29
▲(147.56% Upside)
Technical Analysis
Best Analysts Covering RLAY
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-21.57%
reiterated a buy rating 25 days ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -21.57% per trade.
---